<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Barbe, Michael T.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">DBS Improves FOG in Patients with PD</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">High-frequency deep brain stimulation (DBS) is effective for relief of Parkinson's disease (PD) symptoms. However, studies on the effect of subthalamic nucleus DBS (STN-DBS) on freezing of gait (FOG) have reported inconsistent results, with some suggesting that STN-DBS alleviates FOG [Davis JT et al. Clin Neurol Neurosurg 2006] and others reporting worsening of gait and balance [van Neunen BFL et al. Mov Disord 2008; Krack P et al. N Engl J Med 2003]. This article discusses the the Vercise Implantable Stimulator for Treating Parkinson's Disease trial [VANTAGE; NCT01221948].</style></abstract><number><style face="normal" font="default" size="100%">15</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>